← Back to Patent Explorer
US5124437A Expired / Lapsed US ⏱️ 0.0 years remaining

Galactosamine substitute of poly-ω-substituted-L-glutamic acid (or aspartic acid)

Assignee: Astellas Pharma Inc
•
Filing: 1991-04-23
•
Granted: 1992-06-23
•
Expires: 2011-04-23
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A galactosamine substituted poly-ω-alkyl (or benzyl)-L-glutamic acid (or aspartic acid) is provided and comprises a polypeptide having the recurring unit represented by the formula: ##STR1## wherein X has a value of 60 to 250; n is 1 or 2; and R represents a lower alkyl group or benzyl group, in which a part or all of the peptide in said polypeptide is substituted by an ω-galactosamyl-L-glutamic acid (or aspartic acid) residue represented by the general formula: ##STR2## wherein n is as indicated.

Inventors

  • 👤 Toshihiro Akaike
  • 👤 Ichirou Kitada
  • 👤 Megumi Kunou

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-06 11:46
CPC Classifications
C; C07; C07K; C07K14/00; A; A61; A61K; A61K38/00

Claims Analysis

Total Claims: 4
Claim 1
Independent Claim 85 words
A galactosamine substituted poly-ω-alkyl or benzyl-L-glutamic acid or aspartic acid comprising a polypeptide having a recurring unit represented by the general formula: ##STR10## wherein X has a value of 60 to 250; n is 1 or 2; and R represents a C 1-4 alkyl group or benzyl group, in which a part or all of said recurring units in said polypeptide are substituted by an ω-galactosamyl-L-glutamic acid or aspartic acid residue represented by the formula: ##STR11## wherein n has the same value as described above.
Claim 2
Dependent Claim 85 words
A galactosamine substituted poly-ω-alkyl or benzyl-L-glutamic acid or aspartic acid comprising a polypeptide having a recurring unit represented by the general formula: ##STR10## wherein X has a value of 60 to 250; n is 1 or 2; and R represents a C 1-4 alkyl group or benzyl group, in which a part or all of said recurring units in said polypeptide are substituted by an ω-galactosamyl-L-glutamic acid or aspartic acid residue represented by the formula: ##STR11## wherein n has the same value as described above.
Claim 3
Dependent Claim 131 words
A partially galactosamylated ω-alkyl or benzyl-L-glutamic acid or aspartic acid linear polymer comprising, as recurring units, an ω-alkyl or benzyl-L-glutamic acid or aspartic acid residue: ##STR12## wherein n is 1 or 2 and R represents a C 1-4 alkyl group or benzyl group; and L-glutamic acid or aspartic acid residue: ##STR13## wherein n has the same significance as described above; and, an ω-galactosamyl-L-glutamic acid (or aspartic acid) residue: ##STR14## wherein n has the same significance as described above, and said polymer having from 60 to 250 recurring units, a molecular weight of 8,000 to 71,000 and the following ratio of the respective recurring units: an ω-alkyl or benzyl-L-glutamic acid or aspartic acid residue: 0-97% an L-glutamic acid or aspartic acid residue: 0-87% and an ω-galactosamyl-L-glutamic acid or aspartic acid residue: 3-100%.
Claim 4
Dependent Claim 131 words
A partially galactosamylated ω-alkyl or benzyl-L-glutamic acid or aspartic acid linear polymer comprising, as recurring units, an ω-alkyl or benzyl-L-glutamic acid or aspartic acid residue: ##STR12## wherein n is 1 or 2 and R represents a C 1-4 alkyl group or benzyl group; and L-glutamic acid or aspartic acid residue: ##STR13## wherein n has the same significance as described above; and, an ω-galactosamyl-L-glutamic acid (or aspartic acid) residue: ##STR14## wherein n has the same significance as described above, and said polymer having from 60 to 250 recurring units, a molecular weight of 8,000 to 71,000 and the following ratio of the respective recurring units: an ω-alkyl or benzyl-L-glutamic acid or aspartic acid residue: 0-97% an L-glutamic acid or aspartic acid residue: 0-87% and an ω-galactosamyl-L-glutamic acid or aspartic acid residue: 3-100%.

References Cited (Backward Citations)

JPS6042335A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1995-06-23 1995-12-23 1996-06-23 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1999-06-23 1999-12-23 2000-06-23 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2003-06-23 2003-12-23 2004-06-23 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag